BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 29661801)

  • 1. Anti-CA15.3 and Anti-CA125 Antibodies and Ovarian Cancer Risk: Results from the EPIC Cohort.
    Cramer DW; Fichorova RN; Terry KL; Yamamoto H; Vitonis AF; Ardanaz E; Aune D; Boeing H; Brändstedt J; Boutron-Ruault MC; Chirlaque MD; Dorronsoro M; Dossus L; Duell EJ; Gram IT; Gunter M; Hansen L; Idahl A; Johnson T; Khaw KT; Krogh V; Kvaskoff M; Mattiello A; Matullo G; Merritt MA; Nodin B; Orfanos P; Onland-Moret NC; Palli D; Peppa E; Quirós JR; Sánchez-Perez MJ; Severi G; Tjønneland A; Travis RC; Trichopoulou A; Tumino R; Weiderpass E; Fortner RT; Kaaks R
    Cancer Epidemiol Biomarkers Prev; 2018 Jul; 27(7):790-804. PubMed ID: 29661801
    [No Abstract]   [Full Text] [Related]  

  • 2. Puerperal mastitis: a reproductive event of importance affecting anti-mucin antibody levels and ovarian cancer risk.
    Cramer DW; Williams K; Vitonis AF; Yamamoto HS; Stuebe A; Welch WR; Titus L; Fichorova RN
    Cancer Causes Control; 2013 Nov; 24(11):1911-23. PubMed ID: 23925696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
    Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
    BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlates of circulating ovarian cancer early detection markers and their contribution to discrimination of early detection models: results from the EPIC cohort.
    Fortner RT; Vitonis AF; Schock H; Hüsing A; Johnson T; Fichorova RN; Fashemi T; Yamamoto HS; Tjønneland A; Hansen L; Overvad K; Boutron-Ruault MC; Kvaskoff M; Severi G; Boeing H; Trichopoulou A; Benetou V; La Vecchia C; Palli D; Sieri S; Tumino R; Matullo G; Mattiello A; Onland-Moret NC; Peeters PH; Weiderpass E; Gram IT; Jareid M; Quirós JR; Duell EJ; Sánchez MJ; Chirlaque MD; Ardanaz E; Larrañaga N; Nodin B; Brändstedt J; Idahl A; Khaw KT; Allen N; Gunter M; Johansson M; Dossus L; Merritt MA; Riboli E; Cramer DW; Kaaks R; Terry KL
    J Ovarian Res; 2017 Mar; 10(1):20. PubMed ID: 28320479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphisms of MUC16 (CA125) and MUC1 (CA15.3) in relation to ovarian cancer risk and survival.
    Williams KA; Terry KL; Tworoger SS; Vitonis AF; Titus LJ; Cramer DW
    PLoS One; 2014; 9(2):e88334. PubMed ID: 24551091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic measures comparison for ovarian malignancy risk in Epithelial ovarian cancer patients: a meta-analysis.
    Suri A; Perumal V; Ammalli P; Suryan V; Bansal SK
    Sci Rep; 2021 Aug; 11(1):17308. PubMed ID: 34453074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ovarian cancer early detection by circulating CA125 in the context of anti-CA125 autoantibody levels: Results from the EPIC cohort.
    Fortner RT; Schock H; Le Cornet C; Hüsing A; Vitonis AF; Johnson TS; Fichorova RN; Fashemi T; Yamamoto HS; Tjønneland A; Hansen L; Overvad K; Boutron-Ruault MC; Kvaskoff M; Severi G; Boeing H; Trichopoulou A; Papatesta EM; La Vecchia C; Palli D; Sieri S; Tumino R; Sacerdote C; Mattiello A; Onland-Moret NC; Peeters PH; Bueno-de-Mesquita HBA; Weiderpass E; Quirós JR; Duell EJ; Sánchez MJ; Navarro C; Ardanaz E; Larrañaga N; Nodin B; Jirström K; Idahl A; Lundin E; Khaw KT; Travis RC; Gunter M; Johansson M; Dossus L; Merritt MA; Riboli E; Terry KL; Cramer DW; Kaaks R
    Int J Cancer; 2018 Apr; 142(7):1355-1360. PubMed ID: 29159934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
    Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
    Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors influencing serum concentration of CA125 and CA15-3 in Iranian healthy postmenopausal women.
    Dehaghani AS; Ghiam AF; Hosseini M; Mansouri S; Ghaderi A
    Pathol Oncol Res; 2007; 13(4):360-4. PubMed ID: 18158573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Racial/ethnic differences in average CA125 and CA15.3 values and its correlates among postmenopausal women in the USA.
    Sasamoto N; Vitonis AF; Fichorova RN; Yamamoto HS; Terry KL; Cramer DW
    Cancer Causes Control; 2021 Mar; 32(3):299-309. PubMed ID: 33462738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High grade, advanced, serous ovarian cancer with low serum CA125 levels.
    Asali A; Haj-Yehia N; Zehavi T; Perry T; Beiner M; Fishman A; Kadan Y
    J Obstet Gynaecol; 2021 Oct; 41(7):1107-1111. PubMed ID: 33427544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
    Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Europium Nanoparticle-Based Sialyl-Tn Monoclonal Antibody Discriminates Epithelial Ovarian Cancer-Associated CA125 from Benign Sources.
    Gidwani K; Nadeem N; Huhtinen K; Kekki H; Heinosalo T; Hynninen J; Perheentupa A; Poutanen M; Carpen O; Pettersson K; Lamminmäki U
    J Appl Lab Med; 2019 Nov; 4(3):299-310. PubMed ID: 31659068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of HE4, CA125, and ROMA Diagnostic Accuracy: A Prospective and Multicenter Study for Chinese Women With Epithelial Ovarian Cancer.
    Zhang P; Wang C; Cheng L; Zhang P; Guo L; Liu W; Zhang Z; Huang Y; Ou Q; Wen X; Tian Y
    Medicine (Baltimore); 2015 Dec; 94(52):e2402. PubMed ID: 26717395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spectrally separated dual-label upconversion luminescence lateral flow assay for cancer-specific STn-glycosylation in CA125 and CA15-3.
    Ekman M; Salminen T; Raiko K; Soukka T; Gidwani K; Martiskainen I
    Anal Bioanal Chem; 2024 May; 416(13):3251-3260. PubMed ID: 38584178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.
    Kristjansdottir B; Levan K; Partheen K; Sundfeldt K
    Gynecol Oncol; 2013 Oct; 131(1):52-8. PubMed ID: 23891789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CPH-I and HE4 Are More Favorable Than CA125 in Differentiating Borderline Ovarian Tumors from Epithelial Ovarian Cancer at Early Stages.
    Wang Z; Tao X; Ying C
    Dis Markers; 2019; 2019():6241743. PubMed ID: 31737130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammatory Markers and Risk of Epithelial Ovarian Cancer by Tumor Subtypes: The EPIC Cohort.
    Ose J; Schock H; Tjønneland A; Hansen L; Overvad K; Dossus L; Clavel-Chapelon F; Baglietto L; Boeing H; Trichopolou A; Benetou V; Lagiou P; Masala G; Tagliabue G; Tumino R; Sacerdote C; Mattiello A; Bueno-de-Mesquita HB; Peeters PH; Onland-Moret NC; Weiderpass E; Gram IT; Sánchez S; Obon-Santacana M; Sànchez-Pérez MJ; Larrañaga N; Castaño JM; Ardanaz E; Brändstedt J; Lundin E; Idahl A; Travis RC; Khaw KT; Rinaldi S; Romieu I; Merritt MA; Gunter MJ; Riboli E; Kaaks R; Fortner RT
    Cancer Epidemiol Biomarkers Prev; 2015 Jun; 24(6):951-61. PubMed ID: 25855626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acrylamide and Glycidamide Hemoglobin Adducts and Epithelial Ovarian Cancer: A Nested Case-Control Study in Nonsmoking Postmenopausal Women from the EPIC Cohort.
    Obón-Santacana M; Lujan-Barroso L; Travis RC; Freisling H; Ferrari P; Severi G; Baglietto L; Boutron-Ruault MC; Fortner RT; Ose J; Boeing H; Menéndez V; Sánchez-Cantalejo E; Chamosa S; Castaño JM; Ardanaz E; Khaw KT; Wareham N; Merritt MA; Gunter MJ; Trichopoulou A; Papatesta EM; Klinaki E; Saieva C; Tagliabue G; Tumino R; Sacerdote C; Mattiello A; Bueno-de-Mesquita HB; Peeters PH; Onland-Moret NC; Idahl A; Lundin E; Weiderpass E; Vesper HW; Riboli E; Duell EJ
    Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):127-34. PubMed ID: 26598536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass.
    Moore RG; McMeekin DS; Brown AK; DiSilvestro P; Miller MC; Allard WJ; Gajewski W; Kurman R; Bast RC; Skates SJ
    Gynecol Oncol; 2009 Jan; 112(1):40-6. PubMed ID: 18851871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.